About: drug approval

The European Commission should shelve its patent law proposal

The European Commission is considering an initiative that would permanently hobble the continent's economy, writes Jan Fischer.

Does fast-track drugs approval in EU run too fast?

More than two years after its launch, the EU's fast-track approval process for marketing new drugs, called PRIME, is broadly welcomed by patients and industry, walking the fine line between patients' safety and expediency, and between the need to foster innovation and remaining abuse-proof.